drugset / Trial / NCT03276910
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
Phase 1
Unknown
24 enrolled
Association Athletes For Transparency
Centre d'Investigation Clinique Lyon (CIC) · collabEcole Nationale de Ski et d'Alpinisme (ENSA) · collabPartnership for Clean Competition · collabUniversity of Milan School of Medicine · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).
Timeline
- Start
- 2017-09-08
- Primary completion
- 2017-12-22
- Completion
- 2018-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPREX | Protein / enzyme biologic | 20 iu/kg | Subcutaneous |
| Subject | EPREX | Protein / enzyme biologic | 50 iu/kg | Subcutaneous |